BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 37121981)

  • 1. Postoperative thyroglobulin as a yard-stick for radioiodine therapy: decision tree analysis in a European multicenter series of 1317 patients with differentiated thyroid cancer.
    Giovanella L; Milan L; Roll W; Weber M; Schenke S; Kreissl M; Vrachimis A; Pabst K; Murat T; Petranovic Ovcaricek P; Riemann B; Ceriani L; Campenni A; Görges R
    Eur J Nucl Med Mol Imaging; 2023 Jul; 50(9):2767-2774. PubMed ID: 37121981
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thyroglobulin measurement is the most powerful outcome predictor in differentiated thyroid cancer: a decision tree analysis in a European multicenter series.
    Giovanella L; Milan L; Roll W; Weber M; Schenke S; Kreissl M; Vrachimis A; Pabst K; Murat T; Petranović Ovčariček P; Campenni A; Görges R; Ceriani L
    Clin Chem Lab Med; 2024 May; ():. PubMed ID: 38706105
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low correlation between serum thyroglobulin and
    Thai JN; De Marchena IR; Nehru VM; Landau E; Demissie S; Josemon R; Peti S; Brenner AI
    Clin Imaging; 2022 Jul; 87():1-4. PubMed ID: 35439719
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Letter to the Editor: Postoperative thyroglobulin as a yard-stick for radioiodine therapy: decision tree analysis in a European multicenter series of 1317 patients with differentiated thyroid cancer.
    Sasaki FM; Leal ALG; de Almeida Filho PJ; Mourato FA
    Eur J Nucl Med Mol Imaging; 2024 Feb; 51(3):803-804. PubMed ID: 38017326
    [No Abstract]   [Full Text] [Related]  

  • 5. Thyroglobulin measurement before rhTSH-aided 131I ablation in detecting metastases from differentiated thyroid carcinoma.
    Giovanella L; Ceriani L; Suriano S; Ghelfo A; Maffioli M
    Clin Endocrinol (Oxf); 2008 Oct; 69(4):659-63. PubMed ID: 18363882
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic value of serial serum thyroglobulin determinations after total thyroidectomy for differentiated thyroid cancer.
    Lima N; Cavaliere H; Tomimori E; Knobel M; Medeiros-Neto G
    J Endocrinol Invest; 2002 Feb; 25(2):110-5. PubMed ID: 11929080
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management of differentiated thyroid cancer with rising thyroglobulin and negative diagnostic radioiodine whole body scan.
    Chao M
    Clin Oncol (R Coll Radiol); 2010 Aug; 22(6):438-47. PubMed ID: 20561773
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The value of diagnostic whole-body scanning and serum thyroglobulin in the presence of elevated serum thyrotropin during follow-up of anti-thyroglobulin antibody-positive patients with differentiated thyroid carcinoma who appeared to be free of disease after total thyroidectomy and radioactive iodine ablation.
    Rosario PW; Mineiro Filho AF; Lacerda RX; dos Santos DA; Calsolari MR
    Thyroid; 2012 Feb; 22(2):113-6. PubMed ID: 22224815
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sensitivity of 123I whole-body scan and thyroglobulin in the detection of metastases or recurrent differentiated thyroid cancer.
    de Geus-Oei LF; Oei HY; Hennemann G; Krenning EP
    Eur J Nucl Med Mol Imaging; 2002 Jun; 29(6):768-74. PubMed ID: 12029550
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of radioiodine therapy in differentiated thyroid cancer subjects with elevated serum thyroglobulin and negative whole body scan using 131I with emphasize on the thallium scintigraphy in these subgroups.
    Zakani A; Saghari M; Eftekhari M; Fard-Esfahani A; Fallahi B; Esmaili J; Assadi M
    Eur Rev Med Pharmacol Sci; 2011 Oct; 15(10):1215-21. PubMed ID: 22165686
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Investigating patients with differentiated thyroid carcinoma and elevated serum thyroglobulin but negative whole-body scan].
    Rosário PW; Maia FC; Barroso AL; Purisch S
    Arq Bras Endocrinol Metabol; 2005 Apr; 49(2):246-52. PubMed ID: 16184253
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Re-ablation I-131 activity does not predict treatment success in low- and intermediate-risk patients with differentiated thyroid carcinoma.
    Prpic M; Kruljac I; Kust D; Kirigin LS; Jukic T; Dabelic N; Bolanca A; Kusic Z
    Endocrine; 2016 Jun; 52(3):602-8. PubMed ID: 26732041
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical significance of observation without repeated radioiodine therapy in differentiated thyroid carcinoma patients with positive surveillance whole-body scans and negative thyroglobulin.
    Lim DJ; O JH; Kim MH; Kim JH; Kwon HS; Kim SH; Kang MI; Cha BY; Lee KW; Son HY
    Korean J Intern Med; 2010 Dec; 25(4):408-14. PubMed ID: 21179279
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fluorodeoxyglucose PET/CT in patients with differentiated thyroid cancer and elevated thyroglobulin after total thyroidectomy and (131)I ablation.
    Salvatore B; Paone G; Klain M; Storto G; Nicolai E; D'Amico D; Della Morte AM; Pace L; Salvatore M
    Q J Nucl Med Mol Imaging; 2008 Mar; 52(1):2-8. PubMed ID: 17538522
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic implication of thyroglobulin and quantified whole body scan after initial radioiodine therapy on early prediction of ablation and clinical response for the patients with differentiated thyroid cancer.
    Lim I; Kim SK; Hwang SS; Kim SW; Chung KW; Kang HS; Lee ES
    Ann Nucl Med; 2012 Dec; 26(10):777-86. PubMed ID: 22869417
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Postoperative stimulated thyroglobulin level and recurrence risk stratification in differentiated thyroid cancer.
    Yang X; Liang J; Li TJ; Yang K; Liang DQ; Yu Z; Lin YS
    Chin Med J (Engl); 2015 Apr; 128(8):1058-64. PubMed ID: 25881600
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A user-friendly nomogram for predicting radioiodine refractory differentiated thyroid cancer.
    Meng C; Song J; Long W; Mu Z; Sun Y; Liang J; Lin Y
    Front Endocrinol (Lausanne); 2023; 14():1109439. PubMed ID: 36843580
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum thyroglobulin and 131I whole body scan after recombinant human TSH stimulation in the follow-up of low-risk patients with differentiated thyroid cancer.
    Torlontano M; Crocetti U; D'Aloiso L; Bonfitto N; Di Giorgio A; Modoni S; Valle G; Frusciante V; Bisceglia M; Filetti S; Schlumberger M; Trischitta V
    Eur J Endocrinol; 2003 Jan; 148(1):19-24. PubMed ID: 12534353
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ongoing risk stratification for differentiated thyroid cancer (DTC) - stimulated serum thyroglobulin (Tg) before radioiodine (RAI) ablation, the most potent risk factor of cancer recurrence in M0 patients.
    Krajewska J; Jarząb M; Czarniecka A; Roskosz J; Kukulska A; Handkiewicz-Junak D; Puch Z; Wygoda Z; Paliczka-Cieślik E; Kropińska A; Gubała E; Jurecka-Lubieniecka B; Jarząb B
    Endokrynol Pol; 2016; 67(1):2-11. PubMed ID: 26884109
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Radioiodine whole-body scans, thyroglobulin levels, 99mTc-MIBI scans and computed tomography: results in patients with lung metastases from differentiated thyroid cancer.
    Küçük ON; Gültekin SS; Aras G; Ibiş E
    Nucl Med Commun; 2006 Mar; 27(3):261-6. PubMed ID: 16479246
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.